• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Research Programs

Clinical-based Research

Lymphoma and Myeloma

Collaborative Interactions

Collaborative Interactions

The Lymphoma and Myeloma Program is based on strong interaction between basic and translational investigators dedicated to lymphoma and myeloma research and clinical investigators exploring novel therapies in these diseases.

DF/HCC has enhanced our ability to obtain multidisciplinary, collaborative grants and disease-based investigator-initiated grants. Representative examples of both types of grants are included in the table below.

Grant # Grant Title Pricipal Investigator Project List Number of institutions involved
PO1CA92625 Molecular Targets of Germial Center B-Cell Lymphomas M. Shipp - DFCI Projects:
1)F. Alt - CHB/K Rajewsky - HMS
2) S. Korsmeyer - DFCI
3) M. Shipp - DFCI
4) G Dranoff - DFCI

A) T. Golub - DFCI
B) J. Aster - BWH
C) A. Freedman - DFCI
D) D. Neuberg - DFCI

4 Harvard Institute and Broad Institute
P50CA100707 Spore in Myeloma K. Anderson - DFCI Projects:
1) K. Anderson - DFCI
2) N. Munshi - DFCI
3) D. Kufe - DFCI
4) P. Richardson - DFCI
PO1CA78378 Novel Immune-based Therapies for Multiple Myeloma K. Anderson - DFCI Projects:
1) J. Ritz - DFCI
2) N. Munshi - DFCI
3) K. Anderson - DFCI


The Lymphoma and Myeloma Program also interacts closely with DF/HCC programs such as Biostatistics, Cancer Cell Biology, Cancer Genetics, Cancer Immunology, and Outcomes Research. Given the common interests of the Leukemia and Lymphoma and Myeloma Program members, these two groups collaborate frequently.
In addition to investigator-initiated trials associated with DF/HCC translational research programs, the Lymphoma and Myeloma Program participates in cooperative group and industry-sponsored studies, allowing the Program to address questions that require larger patient numbers. Through these collaborations, DF/HCC Lymphoma and Myeloma Program investigators focus on developing new treatment approaches to specific lymphoid malignancies and optimizing therapies for a broad range of lymphoid tumors. Major areas of emphasis include:

  • New combinations and novel agents
  • Rational therapeutic targets derived from transcriptional profiling
  • Stem cell transplantation (autologous and allogeneic transplantation)
  • Manipulation of host immunity and microenvironment (including tumor vaccines)